Baras AS - Search Results

1

FOXO1 inactivation induces cisplatin resistance in bladder cancer.

Ide H, Goto T, Teramoto Y, Mizushima T, Jiang G, Nagata Y, Inoue S, Baras AS, Kashiwagi E, Miyamoto H. Ide H, et al. Among authors: baras as. Cancer Sci. 2020 Sep;111(9):3397-3400. doi: 10.1111/cas.14557. Epub 2020 Jul 17. Cancer Sci. 2020. PMID: 32678492 Free PMC article.

2

A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder Cancer.

Park JC, Gandhi NM, Carducci MA, Eisenberger MA, Baras AS, Netto GJ, Liu JJ, Drake CG, Schoenberg MP, Bivalacqua TJ, Hahn NM. Park JC, et al. Among authors: baras as. J Urol. 2016 Apr;195(4 Pt 1):880-5. doi: 10.1016/j.juro.2015.11.024. Epub 2015 Nov 18. J Urol. 2016. PMID: 26598426

3

Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation.

Kawahara T, Ide H, Kashiwagi E, Patterson JD, Inoue S, Shareef HK, Aljarah AK, Zheng Y, Baras AS, Miyamoto H. Kawahara T, et al. Among authors: baras as. Am J Cancer Res. 2015 Sep 15;5(10):2959-68. eCollection 2015. Am J Cancer Res. 2015. PMID: 26693052 Free PMC article.

4

Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.

Kashiwagi E, Ide H, Inoue S, Kawahara T, Zheng Y, Reis LO, Baras AS, Miyamoto H. Kashiwagi E, et al. Among authors: baras as. Oncotarget. 2016 Aug 2;7(31):49169-49179. doi: 10.18632/oncotarget.9994. Oncotarget. 2016. PMID: 27322140 Free PMC article.

5

Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?

Brant A, Kates M, Chappidi MR, Patel HD, Sopko NA, Netto GJ, Baras AS, Hahn NM, Pierorazio PM, Bivalacqua TJ. Brant A, et al. Among authors: baras as. Urol Oncol. 2017 Jan;35(1):34.e17-34.e25. doi: 10.1016/j.urolonc.2016.08.005. Epub 2016 Sep 14. Urol Oncol. 2017. PMID: 27639777

6

A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157.

Hahn NM, Bivalacqua TJ, Ross AE, Netto GJ, Baras A, Park JC, Chapman C, Masterson TA, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Jones DR, McElyea K, Sandusky GE, Breen T, Liu Z, Albany C, Moore ML, Loman RL, Reed A, Turner SA, De Abreu FB, Gallagher T, Tsongalis GJ, Plimack ER, Greenberg RE, Geynisman DM. Hahn NM, et al. Clin Cancer Res. 2017 Jun 15;23(12):3003-3011. doi: 10.1158/1078-0432.CCR-16-2267. Epub 2016 Dec 8. Clin Cancer Res. 2017. PMID: 27932416 Free PMC article. Clinical Trial.

7

Intravesical BCG Induces CD4⁺ T-Cell Expansion in an Immune Competent Model of Bladder Cancer.

Kates M, Nirschl T, Sopko NA, Matsui H, Kochel CM, Reis LO, Netto GJ, Hoque MO, Hahn NM, McConkey DJ, Baras AS, Drake CG, Bivalacqua TJ. Kates M, et al. Among authors: baras as. Cancer Immunol Res. 2017 Jul;5(7):594-603. doi: 10.1158/2326-6066.CIR-16-0267. Epub 2017 Jun 6. Cancer Immunol Res. 2017. PMID: 28588015 Free PMC article.

8

Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer.

Kates M, Date A, Yoshida T, Afzal U, Kanvinde P, Babu T, Sopko NA, Matsui H, Hahn NM, McConkey DJ, Baras A, Hanes J, Ensign L, Bivalacqua TJ. Kates M, et al. Clin Cancer Res. 2017 Nov 1;23(21):6592-6601. doi: 10.1158/1078-0432.CCR-17-1082. Epub 2017 Aug 14. Clin Cancer Res. 2017. PMID: 28808039 Free PMC article.

9

Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression.

Kashiwagi E, Inoue S, Mizushima T, Chen J, Ide H, Kawahara T, Reis LO, Baras AS, Netto GJ, Miyamoto H. Kashiwagi E, et al. Among authors: baras as. Br J Cancer. 2018 Jan;118(2):213-223. doi: 10.1038/bjc.2017.393. Epub 2017 Nov 9. Br J Cancer. 2018. PMID: 29123257 Free PMC article.

10

Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.

Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, Brant A, Mikkilineni N, McConkey DJ, Kamat AM, Svatek RS, Porten SP, Meeks JJ, Lerner SP, Dinney CP, Black PC, McKiernan JM, Anderson C, Drake CG, Bivalacqua TJ. Kates M, et al. Among authors: baras as. Clin Cancer Res. 2020 Feb 15;26(4):882-891. doi: 10.1158/1078-0432.CCR-19-1920. Epub 2019 Nov 11. Clin Cancer Res. 2020. PMID: 31712383

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

102 results

Search Page